Researchers found just chemo/radiation was as effective in half of those with earliest stage of disease.
(HealthDay)—For many rectal cancer patients, the prospect of surgery is a worrisome reality, given that the operation can significantly impair both bowel and sexual function.
However, a new study reveals that some cancer patients may fare just as well by forgoing surgery in favor of chemotherapy/radiation and "watchful waiting."
The finding is based on a review of data from 145 rectal cancer patients, all of whom had been diagnosed with stage I, II or III disease. All had chemotherapy and radiation. But about half had surgery while the others staved off the procedure in favor of rigorous tracking of their disease progression—sometimes called "watchful waiting."
"We believe that our results will encourage more doctors to consider this 'watch-and-wait' approach in patients with clinical complete response as an alternative to immediate rectal surgery, at least for some patients," senior study author Dr. Philip Paty said in a news release from the American Society of Clinical Oncology (ASCO).
"From my experience, most patients are willing to accept some risk to defer rectal surgery in hope of avoiding major surgery and preserving rectal function," said Paty, a surgical oncologist at the Memorial Sloan-Kettering Cancer Center in New York City.
The findings are to be presented Monday at the Gastrointestinal Cancers Symposium in San Francisco. ASCO is one of four organizations sponsoring the symposium.
Research presented at medical meetings should be viewed as preliminary until published in a peer-reviewed journal.
The study authors said that the type of patients who would most likely do well without immediate surgery are the up to 50 percent of stage I patients whose tumors typically disappear altogether following initial chemotherapy/radiation treatment. That figure hovers at between 30 percent and 40 percent among stage II and III patients.
The new investigation looked at the experience of rectal cancer patients who were treated between 2006 and 2014 at Memorial Sloan-Kettering.
While all the patients had experienced complete tumor regression following chemotherapy/radiation, only some underwent immediate rectal surgery. The other 73 patients were instead followed with "watchful waiting," which involved follow-up exams every few months.
Ultimately, nearly three-quarters of the non-surgery group remained cancer-free approximately four years later, while about one quarter had to undergo surgery to treat tumor recurrence.
Overall, the four-year survival rate was 91 percent in the no-surgery group vs. 95 percent in the surgery group.
Explore further: Getting chemo first may help in rectal cancer
More information: Visit the American Cancer Society for more on rectal cancer.
Copyright © 2015 HealthDay. All rights reserved.
Medical Xpress on facebook
Related Stories
Getting chemo first may help in rectal cancer
May 15, 2014
(Medical Xpress)—A new phase II study to be presented at the annual meeting of the American Society for Clinical Oncology finds that if chemotherapy is offered before radiation and surgery, more patients ...
Chemotherapy before or after surgery for high-risk bladder cancer improves survival, but is not routinely administered
Apr 14, 2014
Contrary to treatment guidelines for high-risk bladder cancer, chemotherapy before or after surgery is not commonly used in routine clinical practice. The findings are published early online in Cancer, a peer-reviewed journa ...
Secondary analysis of RTOG 0247 demonstrates favorable overall survival rates for rectal cancer patients
Jan 09, 2015
Locally advanced rectal cancer patients who receive preoperative radiation therapy with either irinotecan plus capecitabine or oxaliplatin plus capecitabine have a four-year overall survival rate of 85 percent and 75 percent, ...
Team finds cancer biopsies do not promote cancer spread
Jan 09, 2015
A study of more than 2,000 patients by researchers at Mayo Clinic's campus in Jacksonville, Florida, has dispelled the myth that cancer biopsies cause cancer to spread. In the Jan. 9 online issue of Gut, they s ...
Radiation for prostate cancer linked to secondary cancers, study finds
May 30, 2014
Among men treated for prostate cancer, those who received radiation therapy were more likely to develop bladder or rectal cancer, according to a new study from the University of Michigan Comprehensive Cancer Center.
Recommended for you
Vitamin D may boost colon cancer survival, study finds
31 minutes ago
(HealthDay)—Higher vitamin D levels in patients with advanced colon cancer appear to improve response to chemotherapy and targeted anti-cancer drugs, researchers say.
FDA approved drug extends survival for patients with rare cancer
9 hours ago
Sunitinib, an agent approved for use in several cancers, provides unprecedented antitumor activity in thymic carcinoma, a rare but aggressive tumor of the thymus gland, according to a phase II clinical trial led by a researcher ...
'Survival' protein a target in drug-resistant non-Hodgkin lymphomas
11 hours ago
Melbourne researchers have discovered that targeting a cell 'survival' protein could help treat some lymphomas, including those cancers with genetic defects that make them resistant to many existing therapies.
Study identifies new gene mutations linked to colorectal cancer in African-Americans
12 hours ago
Case Comprehensive Cancer Center researchers have identified new gene mutations unique to colon cancers in African Americans - the population with the highest incidence and death rates of any group for this ...
Revisions to molecular testing guideline continues to give hope to lung cancer patients
14 hours ago
The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) are teaming to revise the evidence-based guideline, "Molecular ...
Beyond prevention: Sulforaphane may find possible use for cancer therapy
15 hours ago
New research has identified one of the key cancer-fighting mechanisms for sulforaphane, and suggests that this much-studied phytochemical may be able to move beyond cancer prevention and toward therapeutic ...
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here to reset your password.
Sign in to get notified via email when new comments are made.
© Medical Xpress 2011-2014, Science X network
Researchers found just chemo/radiation was as effective in half of those with earliest stage of disease.
(HealthDay)—For many rectal cancer patients, the prospect of surgery is a worrisome reality, given that the operation can significantly impair both bowel and sexual function.
However, a new study reveals that some cancer patients may fare just as well by forgoing surgery in favor of chemotherapy/radiation and "watchful waiting."
The finding is based on a review of data from 145 rectal cancer patients, all of whom had been diagnosed with stage I, II or III disease. All had chemotherapy and radiation. But about half had surgery while the others staved off the procedure in favor of rigorous tracking of their disease progression—sometimes called "watchful waiting."
"We believe that our results will encourage more doctors to consider this 'watch-and-wait' approach in patients with clinical complete response as an alternative to immediate rectal surgery, at least for some patients," senior study author Dr. Philip Paty said in a news release from the American Society of Clinical Oncology (ASCO).
"From my experience, most patients are willing to accept some risk to defer rectal surgery in hope of avoiding major surgery and preserving rectal function," said Paty, a surgical oncologist at the Memorial Sloan-Kettering Cancer Center in New York City.
The findings are to be presented Monday at the Gastrointestinal Cancers Symposium in San Francisco. ASCO is one of four organizations sponsoring the symposium.
Research presented at medical meetings should be viewed as preliminary until published in a peer-reviewed journal.
The study authors said that the type of patients who would most likely do well without immediate surgery are the up to 50 percent of stage I patients whose tumors typically disappear altogether following initial chemotherapy/radiation treatment. That figure hovers at between 30 percent and 40 percent among stage II and III patients.
The new investigation looked at the experience of rectal cancer patients who were treated between 2006 and 2014 at Memorial Sloan-Kettering.
While all the patients had experienced complete tumor regression following chemotherapy/radiation, only some underwent immediate rectal surgery. The other 73 patients were instead followed with "watchful waiting," which involved follow-up exams every few months.
Ultimately, nearly three-quarters of the non-surgery group remained cancer-free approximately four years later, while about one quarter had to undergo surgery to treat tumor recurrence.
Overall, the four-year survival rate was 91 percent in the no-surgery group vs. 95 percent in the surgery group.
Explore further: Getting chemo first may help in rectal cancer
More information: Visit the American Cancer Society for more on rectal cancer.
Copyright © 2015 HealthDay. All rights reserved.
Medical Xpress on facebook
Related Stories
Getting chemo first may help in rectal cancer
May 15, 2014
(Medical Xpress)—A new phase II study to be presented at the annual meeting of the American Society for Clinical Oncology finds that if chemotherapy is offered before radiation and surgery, more patients ...
Chemotherapy before or after surgery for high-risk bladder cancer improves survival, but is not routinely administered
Apr 14, 2014
Contrary to treatment guidelines for high-risk bladder cancer, chemotherapy before or after surgery is not commonly used in routine clinical practice. The findings are published early online in Cancer, a peer-reviewed journa ...
Secondary analysis of RTOG 0247 demonstrates favorable overall survival rates for rectal cancer patients
Jan 09, 2015
Locally advanced rectal cancer patients who receive preoperative radiation therapy with either irinotecan plus capecitabine or oxaliplatin plus capecitabine have a four-year overall survival rate of 85 percent and 75 percent, ...
Team finds cancer biopsies do not promote cancer spread
Jan 09, 2015
A study of more than 2,000 patients by researchers at Mayo Clinic's campus in Jacksonville, Florida, has dispelled the myth that cancer biopsies cause cancer to spread. In the Jan. 9 online issue of Gut, they s ...
Radiation for prostate cancer linked to secondary cancers, study finds
May 30, 2014
Among men treated for prostate cancer, those who received radiation therapy were more likely to develop bladder or rectal cancer, according to a new study from the University of Michigan Comprehensive Cancer Center.
Recommended for you
Vitamin D may boost colon cancer survival, study finds
31 minutes ago
(HealthDay)—Higher vitamin D levels in patients with advanced colon cancer appear to improve response to chemotherapy and targeted anti-cancer drugs, researchers say.
FDA approved drug extends survival for patients with rare cancer
9 hours ago
Sunitinib, an agent approved for use in several cancers, provides unprecedented antitumor activity in thymic carcinoma, a rare but aggressive tumor of the thymus gland, according to a phase II clinical trial led by a researcher ...
'Survival' protein a target in drug-resistant non-Hodgkin lymphomas
11 hours ago
Melbourne researchers have discovered that targeting a cell 'survival' protein could help treat some lymphomas, including those cancers with genetic defects that make them resistant to many existing therapies.
Study identifies new gene mutations linked to colorectal cancer in African-Americans
12 hours ago
Case Comprehensive Cancer Center researchers have identified new gene mutations unique to colon cancers in African Americans - the population with the highest incidence and death rates of any group for this ...
Revisions to molecular testing guideline continues to give hope to lung cancer patients
14 hours ago
The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) are teaming to revise the evidence-based guideline, "Molecular ...
Beyond prevention: Sulforaphane may find possible use for cancer therapy
15 hours ago
New research has identified one of the key cancer-fighting mechanisms for sulforaphane, and suggests that this much-studied phytochemical may be able to move beyond cancer prevention and toward therapeutic ...
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here
to reset your password.
Sign in to get notified via email when new comments are made.
© Medical Xpress 2011-2014, Science X network
0 comments:
Post a Comment